Patrizia Farci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Patrizia Farci has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Coiana
Genetic and Genomic Laboratory, Pediatric Children Hospital “A. Cao”, ASL 8 Cagliari, 09121 Cagliari, Italy
4 shared publications Giovanna Peddis
Dipartimento di Scienze Mediche, Università di Cagliari, Cagliari, Italy
4 shared publicationsAngelo Balestrieri
Dipartimento di Scienze Mediche, Università di Cagliari, Cagliari, Italy
3 shared publicationsGiacomo Diaz
Cytomorphology, University of Cagliari, SS 554 Bivio Sestu, 09042 Cagliari, Italy
3 shared publicationsGiancarlo Serra
Liver Unit, Department of Internal Medicine, University of Cagliari, Italy
3 shared publicationsHarvey J. Alter
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892
3 shared publications
Latest Publications
- Open Access
- 1 January 2007
- Published by Bentham Science Publishers Ltd. in Clinical Practice & Epidemiology in Mental Health
- Vol. 3 (1) , 22
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
Mood and anxiety symptoms in chronic hepatitis C (CHC) may be related to the patient awareness of the diagnosis and prognosis, to side effects induced by interferon (IFN)-alpha treatment, as well as to substance abuse. However, the observation of metabolic alterations in patients with CHC has led to hypothesize a direct effect of hepatitis C virus (HCV) on brain function. This study was aimed at elucidating whether CHC is associated with specific anxiety or mood disorders independently of confounding factors.
- 1 January 2007
- Published by Bentham Science Publishers Ltd. in Clinical Practice & Epidemiology in Mental Health
- Vol. 3 (1) , 22
Open AccessAssociation of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
Mood and anxiety symptoms in chronic hepatitis C (CHC) may be related to the patient awareness of the diagnosis and prognosis, to side effects induced by interferon (IFN)-alpha treatment, as well as to substance abuse. However, the observation of metabolic alterations in patients with CHC has led to hypothesize a direct effect of hepatitis C virus (HCV) on brain function. This study was aimed at elucidating whether CHC is associated with specific anxiety or mood disorders independently of confounding factors.
- Open Access
- 29 August 2006
- Published by Wolters Kluwer Health in Hepatology
- Vol. 44 (3) , 536-539
Treatment of chronic hepatitis D: New advances, old challenges
- 29 August 2006
- Published by Wolters Kluwer Health in Hepatology
- Vol. 44 (3) , 536-539
Open AccessTreatment of chronic hepatitis D: New advances, old challenges
- 30 May 2006
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (22) , 8475-8480
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively
Perinatal infection with hepatitis C virus (HCV) is characterized by a wide range of alanine aminotransferase (ALT) levels. The mechanisms responsible for this variability are unknown. We examined whether the evolution of the HCV quasispecies was associated with different ALT profiles in perinatally infected children. Sequences within HCV envelope 1 and 2 genes, inclusive of the hypervariable region 1, the viral load, and the nascent humoral immunity were analyzed in serial serum samples from 12 perinatally infected children prospectively followed for a median of 53 months. These patients were selected to represent two different ALT patterns during the first year of life: 6 had high levels (maximum values ranging from 4.2 to 30 times the normal upper limit), and 6 had normal or slightly elevated levels (P= 0.002). The two patterns of viral evolution persisted over time and did not correlate with viral load or genotype. Our study demonstrates that, in perinatally infected children, the evolution of HCV quasispecies correlates with hepatic injury.
- 30 May 2006
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (22) , 8475-8480
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively
Perinatal infection with hepatitis C virus (HCV) is characterized by a wide range of alanine aminotransferase (ALT) levels. The mechanisms responsible for this variability are unknown. We examined whether the evolution of the HCV quasispecies was associated with different ALT profiles in perinatally infected children. Sequences within HCV envelope 1 and 2 genes, inclusive of the hypervariable region 1, the viral load, and the nascent humoral immunity were analyzed in serial serum samples from 12 perinatally infected children prospectively followed for a median of 53 months. These patients were selected to represent two different ALT patterns during the first year of life: 6 had high levels (maximum values ranging from 4.2 to 30 times the normal upper limit), and 6 had normal or slightly elevated levels (P= 0.002). The two patterns of viral evolution persisted over time and did not correlate with viral load or genotype. Our study demonstrates that, in perinatally infected children, the evolution of HCV quasispecies correlates with hepatic injury.
- 1 June 2004
- Published by Elsevier in Gastroenterology
- Vol. 126 (7) , 1740-1749
Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis
- 1 June 2004
- Published by Elsevier in Gastroenterology
- Vol. 126 (7) , 1740-1749
Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis
- 1 January 2003
- Published by Elsevier in Journal of Hepatology
- Vol. 39, 212-219
Delta hepatitis: an update
- 1 January 2003
- Published by Elsevier in Journal of Hepatology
- Vol. 39, 212-219
Delta hepatitis: an update
- Open Access
- 31 May 2002
- Published by Elsevier in Journal of Hepatology
- Vol. 36 (5) , 582-585
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989;244:359–362]
- 31 May 2002
- Published by Elsevier in Journal of Hepatology
- Vol. 36 (5) , 582-585
Open AccessChoo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989;244:359–362]
- Open Access
- 5 March 2002
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (5) , 3081-3086
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
Despite recent treatment advances, the majority of patients with chronic hepatitis C fail to respond to antiviral therapy. Although the genetic basis for this resistance is unknown, accumulated evidence suggests that changes in the heterogeneous viral population (quasispecies) may be an important determinant of viral persistence and response to therapy. Sequences within hepatitis C virus (HCV) envelope 1 and envelope 2 genes, inclusive of the hypervariable region 1, were analyzed in parallel with the level of viral replication in serial serum samples obtained from 23 patients who exhibited different patterns of response to therapy and from untreated controls. Our study provides evidence that although the viral diversity before treatment does not predict the response to treatment, the early emergence and dominance of a single viral variant distinguishes patients who will have a sustained therapeutic response from those who subsequently will experience a breakthrough or relapse. A dramatic reduction in genetic diversity leading to an increasingly homogeneous viral population was a consistent feature associated with viral clearance in sustained responders and was independent of HCV genotype. The persistence of variants present before treatment in patients who fail to respond or who experience a breakthrough during therapy strongly suggests the preexistence of viral strains with inherent resistance to IFN. Thus, the study of the evolution of the HCV quasispecies provides prognostic information as early as the first 2 weeks after starting therapy and opens perspectives for elucidating the mechanisms of treatment failure in chronic hepatitis C.
- 5 March 2002
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (5) , 3081-3086
Open AccessEarly changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
Despite recent treatment advances, the majority of patients with chronic hepatitis C fail to respond to antiviral therapy. Although the genetic basis for this resistance is unknown, accumulated evidence suggests that changes in the heterogeneous viral population (quasispecies) may be an important determinant of viral persistence and response to therapy. Sequences within hepatitis C virus (HCV) envelope 1 and envelope 2 genes, inclusive of the hypervariable region 1, were analyzed in parallel with the level of viral replication in serial serum samples obtained from 23 patients who exhibited different patterns of response to therapy and from untreated controls. Our study provides evidence that although the viral diversity before treatment does not predict the response to treatment, the early emergence and dominance of a single viral variant distinguishes patients who will have a sustained therapeutic response from those who subsequently will experience a breakthrough or relapse. A dramatic reduction in genetic diversity leading to an increasingly homogeneous viral population was a consistent feature associated with viral clearance in sustained responders and was independent of HCV genotype. The persistence of variants present before treatment in patients who fail to respond or who experience a breakthrough during therapy strongly suggests the preexistence of viral strains with inherent resistance to IFN. Thus, the study of the evolution of the HCV quasispecies provides prognostic information as early as the first 2 weeks after starting therapy and opens perspectives for elucidating the mechanisms of treatment failure in chronic hepatitis C.
- 1 November 2001
- Published by Elsevier in Clinics in Liver Disease
- Vol. 5 (4) , 895-916
HEPATITIS C VIRUS: The Importance of Viral Heterogeneity
- 1 November 2001
- Published by Elsevier in Clinics in Liver Disease
- Vol. 5 (4) , 895-916
HEPATITIS C VIRUS: The Importance of Viral Heterogeneity
- Top Cited Papers
- 14 April 2000
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 288 (5464) , 339-344
The Outcome of Acute Hepatitis C Predicted by the Evolution of the Viral Quasispecies
The mechanisms by which hepatitis C virus (HCV) induces chronic infection in the vast majority of infected individuals are unknown. Sequences within the HCV E1 and E2 envelope genes were analyzed during the acute phase of hepatitis C in 12 patients with different clinical outcomes. Acute resolving hepatitis was associated with relative evolutionary stasis of the heterogeneous viral population (quasispecies), whereas progressing hepatitis correlated with genetic evolution of HCV. Consistent with the hypothesis of selective pressure by the host immune system, the sequence changes occurred almost exclusively within the hypervariable region 1 of the E2 gene and were temporally correlated with antibody seroconversion. These data indicate that the evolutionary dynamics of the HCV quasispecies during the acute phase of hepatitis C predict whether the infection will resolve or become chronic.
- 14 April 2000
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 288 (5464) , 339-344
Top Cited PapersThe Outcome of Acute Hepatitis C Predicted by the Evolution of the Viral Quasispecies
The mechanisms by which hepatitis C virus (HCV) induces chronic infection in the vast majority of infected individuals are unknown. Sequences within the HCV E1 and E2 envelope genes were analyzed during the acute phase of hepatitis C in 12 patients with different clinical outcomes. Acute resolving hepatitis was associated with relative evolutionary stasis of the heterogeneous viral population (quasispecies), whereas progressing hepatitis correlated with genetic evolution of HCV. Consistent with the hypothesis of selective pressure by the host immune system, the sequence changes occurred almost exclusively within the hypervariable region 1 of the E2 gene and were temporally correlated with antibody seroconversion. These data indicate that the evolutionary dynamics of the HCV quasispecies during the acute phase of hepatitis C predict whether the infection will resolve or become chronic.
- 1 January 2000
- Vol. 20 (1) , 103-26
Clinical significance of hepatitis C virus genotypes and quasispecies.
Hepatitis C virus (HCV) is a major cause of morbidity and mortality worldwide. The infection becomes chronic in about 85% of infected individuals, in the face of a strong humoral and cellular immune response. One of the most important features of HCV is its high degree of genetic variability, which is due to the inherent low fidelity of the viral replication machinery. As a consequence, HCV circulates in vivo as a population of divergent, albeit closely related, genomes exhibiting a distribution that follows the model referred to as a quasispecies. The genetic variability of HCV is complex and has been classified into four hierarchical strata: genotypes, subgenotypes, isolates, and quasispecies. Over the past few years, an extraordinary interest has been focused on the biologic and clinical implications of the genetic variability of HCV. Although there is consensus that the genotypes may influence the out come of antiviral therapy, their clinical significance in the natural history of the disease, as well as in transmission, infectivity, and pathogenesis of HCV infection, remains elusive. Conversely, evidence has accumulated that the quasispecies nature of HCV provides a large reservoir of biologically different viral variants that may have important clinical implications for viral persistence by immune escape mechanisms, for the generation of antiviral drug resistance, and for the development of an effective vaccine. This article reviews the state of the art on the biologic and clinical implications of the genetic variability of HCV.
- 1 January 2000
- Vol. 20 (1) , 103-26
Clinical significance of hepatitis C virus genotypes and quasispecies.
Hepatitis C virus (HCV) is a major cause of morbidity and mortality worldwide. The infection becomes chronic in about 85% of infected individuals, in the face of a strong humoral and cellular immune response. One of the most important features of HCV is its high degree of genetic variability, which is due to the inherent low fidelity of the viral replication machinery. As a consequence, HCV circulates in vivo as a population of divergent, albeit closely related, genomes exhibiting a distribution that follows the model referred to as a quasispecies. The genetic variability of HCV is complex and has been classified into four hierarchical strata: genotypes, subgenotypes, isolates, and quasispecies. Over the past few years, an extraordinary interest has been focused on the biologic and clinical implications of the genetic variability of HCV. Although there is consensus that the genotypes may influence the out come of antiviral therapy, their clinical significance in the natural history of the disease, as well as in transmission, infectivity, and pathogenesis of HCV infection, remains elusive. Conversely, evidence has accumulated that the quasispecies nature of HCV provides a large reservoir of biologically different viral variants that may have important clinical implications for viral persistence by immune escape mechanisms, for the generation of antiviral drug resistance, and for the development of an effective vaccine. This article reviews the state of the art on the biologic and clinical implications of the genetic variability of HCV.